ATE482398T1 - Verfahren zur stratifizierung von herzinsuffizienz - Google Patents

Verfahren zur stratifizierung von herzinsuffizienz

Info

Publication number
ATE482398T1
ATE482398T1 AT06754992T AT06754992T ATE482398T1 AT E482398 T1 ATE482398 T1 AT E482398T1 AT 06754992 T AT06754992 T AT 06754992T AT 06754992 T AT06754992 T AT 06754992T AT E482398 T1 ATE482398 T1 AT E482398T1
Authority
AT
Austria
Prior art keywords
heart failure
stratification
preprobnp
devices
amount
Prior art date
Application number
AT06754992T
Other languages
English (en)
Inventor
Ildiko Amann-Zalan
Bernhard Trauth
Otero Jose Miguel Rivera
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE482398T1 publication Critical patent/ATE482398T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Electrotherapy Devices (AREA)
  • External Artificial Organs (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AT06754992T 2005-05-09 2006-05-03 Verfahren zur stratifizierung von herzinsuffizienz ATE482398T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010043A EP1722232A1 (de) 2005-05-09 2005-05-09 Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
PCT/EP2006/062031 WO2006120152A1 (en) 2005-05-09 2006-05-03 Devices and methods for diagnosing or predicting early stage cardiac dysfunctions

Publications (1)

Publication Number Publication Date
ATE482398T1 true ATE482398T1 (de) 2010-10-15

Family

ID=34936290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754992T ATE482398T1 (de) 2005-05-09 2006-05-03 Verfahren zur stratifizierung von herzinsuffizienz

Country Status (9)

Country Link
US (1) US20110104813A1 (de)
EP (2) EP1722232A1 (de)
JP (1) JP4927825B2 (de)
CN (2) CN103091497A (de)
AT (1) ATE482398T1 (de)
CA (1) CA2605247A1 (de)
DE (1) DE602006017058D1 (de)
ES (1) ES2352351T3 (de)
WO (1) WO2006120152A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion
CN106908603B (zh) 2007-01-25 2019-04-02 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
WO2010126370A2 (en) 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
CN103370619B (zh) * 2010-11-29 2016-01-20 美艾利尔圣地亚哥有限公司 诊断或风险预测心力衰竭的方法和试剂
WO2014023820A1 (en) * 2012-08-09 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic of heart failure
EP3206032B1 (de) * 2014-10-10 2019-02-27 Akira Matsumori Verfahren zur detektion eines patienten mit herzversagen, verfahren zur unterscheidung von herzkrankheiten, testreagens für herzversagen, testkit für herzversagen, vorrichtung zur detektion von herzversagen und programm zur detektion von herzversagen
US11193947B2 (en) 2016-06-03 2021-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
EP3464339A4 (de) * 2016-06-03 2019-12-25 Cedars-Sinai Medical Center Proteolytischer test von b-typ-natriuretischem peptid zur beurteilung des risikos von herz-kreislauf-erkrankungen
CN109791139A (zh) * 2016-08-09 2019-05-21 大塚制药株式会社 使用尿液生物标记的阿兹海默氏症的辅助诊断方法
JP7414281B2 (ja) * 2017-08-08 2024-01-16 クイーンズランド ユニバーシティ オブ テクノロジー 初期心不全の診断方法
US11255844B2 (en) * 2018-03-06 2022-02-22 Fresenius Medical Care Holdings, Inc. Peritoneal dialysis systems and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
JP2676114B2 (ja) * 1990-04-16 1997-11-12 塩野義製薬株式会社 ｈＢＮＰを認識するモノクローナル抗体および該抗体を用いるｈＢＮＰの免疫測定法
PL204235B1 (pl) * 1999-01-29 2009-12-31 Roche Diagnostics Gmbh Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
AUPS169202A0 (en) * 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
WO2004046729A2 (en) * 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
US7092759B2 (en) * 2003-07-30 2006-08-15 Medtronic, Inc. Method of optimizing cardiac resynchronization therapy using sensor signals of septal wall motion
US7887750B2 (en) * 2004-05-05 2011-02-15 Bayer Healthcare Llc Analytical systems, devices, and cartridges therefor
EP1722232A1 (de) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Diagnose oder zur Früherkennung der kardialen Dysfunktion

Also Published As

Publication number Publication date
DE602006017058D1 (de) 2010-11-04
EP1880221B1 (de) 2010-09-22
CN101171517B (zh) 2013-10-09
ES2352351T3 (es) 2011-02-17
JP4927825B2 (ja) 2012-05-09
CA2605247A1 (en) 2006-11-16
EP1722232A1 (de) 2006-11-15
JP2008541078A (ja) 2008-11-20
US20110104813A1 (en) 2011-05-05
WO2006120152A1 (en) 2006-11-16
EP1880221A1 (de) 2008-01-23
CN101171517A (zh) 2008-04-30
CN103091497A (zh) 2013-05-08
HK1119771A1 (en) 2009-03-13

Similar Documents

Publication Publication Date Title
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ATE514950T1 (de) Verfahren zur untersuchung von sepsis bei menschen
BRPI0410261A (pt) método de detecção de probnp natural
ATE415662T1 (de) Bestimmung der tatsächlichen zeit, die ein prozessor bei der ausführung eines codeteiles aufwendet
DE602005024639D1 (de) Verfahren und Gerät zur Diagnose des Ermüdungsversagens von Turboladern
DK1974210T3 (da) Fremgangsmåde til diagnosticering af polycystisk nyresygdom
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
WO2004057341A3 (en) Cvd assay
ATE524561T1 (de) Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
ATE473448T1 (de) Verfahren zur diagnose von herz-kreislauf- krankheiten
DE602007010644D1 (de) Biomarker zur beurteilung der leberfunktion
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
ATE515574T1 (de) Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen
EP1767652A4 (de) Genmarker und dessen verwendung
ATE437182T1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum
ATE339683T1 (de) Verfahren zur detektion und konzentrationsbestimmung von schwefelfreien odoriermitteln in erd- oder brenngas
DE60329500D1 (de) Verfahren zur identifikation von salzempfindlichen personen
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1880221

Country of ref document: EP